<div class="gmail_quote">   From:    <a href="mailto:slim.slama@hcuge.ch">slim.slama@hcuge.ch</a><br>   <br><br>It is interesting to note that Novartis is currently massively investing in China, putting itd R&D investment in India on hold.<br>
<br>See the following article with related references in a Canadian biotech blog:<br><br><a href="http://crossborderbiotech.ca/2009/11/12/trends-update-ip-constituencies-novartis-ceo-vasella-calls-upcoming-gleevec-decision-a-turning-point-for-rd-in-india/" target="_blank">http://crossborderbiotech.ca/2009/11/12/trends-update-ip-constituencies-novartis-ceo-vasella-calls-upcoming-gleevec-decision-a-turning-point-for-rd-in-india/</a><br>
<br>As to the Glivec case, Novartis has posted the following responses on its website:<br><br>History of Glivec in India: <a href="http://www.novartis.com/downloads/about-novartis/glivec-history-india.pdf" target="_blank">http://www.novartis.com/downloads/about-novartis/glivec-history-india.pdf</a><br>
<br>and Glivec Patent Case in India: FACT vs. FICTION:<br><br><a href="http://www.novartis.com/downloads/about-novartis/facts-vs-fiction-india-glivec-patent-case.pdf" target="_blank">http://www.novartis.com/downloads/about-novartis/facts-vs-fiction-india-glivec-patent-case.pdf</a><br>
<br>SpicyIP blog has several interesting posts on the IPR politics in India, the case of Glivec is discussed here:<br><br><a href="http://spicyipindia.blogspot.com/2007/09/novartis-patent-saga-flawed-strategy.html" target="_blank">http://spicyipindia.blogspot.com/2007/09/novartis-patent-saga-flawed-strategy.html</a><br>
<br>see also:<a href="http://spicyipindia.blogspot.com/2009/07/breaking-news-novartis-loses-glivec.html" target="_blank">http://spicyipindia.blogspot.com/2009/07/breaking-news-novartis-loses-glivec.html</a><br><br></div>